Close Menu

NEW YORK (GenomeWeb) – LIG Biowise, a UK firm developing point-of-care molecular diagnostics to help combat antimicrobial resistance, has raised £1.8 million ($2.5 million) in a Series A funding round.

The round was led by Phoenix Bridge, a venture capital investor based in Hong Kong, and also included private investors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.